Haldol

Delirium, Schizophrenia, Schizophrenia + 9 more
Treatment
2 FDA approvals
20 Active Studies for Haldol

What is Haldol

HaloperidolThe Generic name of this drug
Treatment SummaryHaloperidol is a medication used to treat psychotic disorders such as schizophrenia, Tourette syndrome, and severe behavioral states. It works by blocking dopamine receptors in the brain, which helps reduce symptoms of psychosis. Haloperidol is an effective and widely used drug, but it can cause side effects such as movement disorders, sedation, weight gain, and changes in prolactin levels. It can also interact with other drugs and has been found to be affected by a person's genetics. Haloperidol is a first-generation antipsychotic drug which has largely been replaced by newer, second- or third-generation antipsych
Haldolis the brand name
image of different drug pills on a surface
Haldol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Haldol
Haloperidol
1971
300

Approved as Treatment by the FDA

Haloperidol, otherwise known as Haldol, is approved by the FDA for 2 uses which include Gilles de la Tourette's Syndrome and Tourette Syndrome .
Gilles de la Tourette's Syndrome
Helps manage Gilles de la Tourette's Syndrome
Tourette Syndrome
Helps manage Gilles de la Tourette's Syndrome

Effectiveness

How Haldol Affects PatientsHaloperidol is an antipsychotic drug used to treat the positive symptoms of schizophrenia, such as hearing voices, aggression, and disorganized speech. However, it can also cause side effects like movement disorders, drowsiness, weight gain, and a change in the level of the hormone prolactin. Compared to other first-generation antipsychotics, haloperidol usually has fewer side effects. Taking haloperidol long-term can lead to a condition called tardive dyskinesia, which is characterized by involuntary, jerky movements. Haloperidol can also cause a serious syndrome called Neurole
How Haldol works in the bodyHaloperidol is an antipsychotic medication that helps decrease psychotic symptoms by blocking dopamine receptors in the brain, particularly in the limbic system. It works by competing with dopamine for its receptor, effectively preventing dopamine from stimulating the nerve cells and reducing the abnormal activity associated with psychosis. Haloperidol also blocks other types of receptors in the autonomic system, which helps reduce nausea and vomiting. It can cause unpleasant side effects, such as extrapyramidal symptoms, due to its tight binding to dopamine receptors. Therefore, newer antipsychotic medications with a lower affinity for dopamine receptors have been developed to reduce the risk of these symptoms

When to interrupt dosage

The advised measure of Haldol is contingent upon the designated state, such as Palliative Care, aggressive response and phencyclidine. Dosage shifts, in light of the technique of delivery featured in the table beneath.
Condition
Dosage
Administration
Obsessive-Compulsive Disorder
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Tourette Syndrome
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
phencyclidine
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Nausea
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Schizophrenia
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Aggression
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Palliative Treatment
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Severe Disruptive Behaviour Disorders
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Huntington Disease
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Delirium
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
severe Hyperactivity
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular
Schizophrenia
5.0 mg/mL, , 2.0 mg/mL, 1.0 mg, 2.0 mg, 5.0 mg, 10.0 mg, 0.5 mg, 20.0 mg, 50.0 mg/mL, 100.0 mg/mL, 1.5 mg, 500.0 mg/mL, 70.52 mg/mL, 141.04 mg/mL
, Injection, solution, Injection, solution - Intramuscular, Intramuscular, Oral, Solution, concentrate, Solution, concentrate - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Injection - Intramuscular, Injection, Liquid - Intramuscular, Liquid, Solution - Intramuscular

Warnings

Haldol Contraindications
Condition
Risk Level
Notes
Coma
Do Not Combine
Asthma
Do Not Combine
Parkinson's Disease
Do Not Combine
Mental Depression
Do Not Combine
Basal Ganglia Lesions
Do Not Combine
Mental Depression
Do Not Combine
There are 20 known major drug interactions with Haldol.
Common Haldol Drug Interactions
Drug Name
Risk Level
Description
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Haloperidol.
Amisulpride
Major
Haloperidol may increase the antipsychotic activities of Amisulpride.
Azelastine
Major
Haloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Cariprazine
Major
The metabolism of Cariprazine can be decreased when combined with Haloperidol.
Eliglustat
Major
The metabolism of Eliglustat can be decreased when combined with Haloperidol.
Haldol Toxicity & Overdose RiskTests have found that the toxic dose of this drug for rats is 71mg/kg.
image of a doctor in a lab doing drug, clinical research

Haldol Novel Uses: Which Conditions Have a Clinical Trial Featuring Haldol?

285 active trials are underway assessing the potential of Haldol to alleviate Obsessive-Compulsive Disorder, provide Palliative Care and counter phencyclidine toxicity.
Condition
Clinical Trials
Trial Phases
Schizophrenia
97 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 4, Phase 1, Phase 2
Obsessive-Compulsive Disorder
66 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1, Early Phase 1
Schizophrenia
32 Actively Recruiting
Early Phase 1, Not Applicable, Phase 4
Huntington Disease
5 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Aggression
1 Actively Recruiting
Not Applicable
Nausea
0 Actively Recruiting
Severe Disruptive Behaviour Disorders
1 Actively Recruiting
Phase 2
Tourette Syndrome
0 Actively Recruiting
Palliative Treatment
1 Actively Recruiting
Phase 3
Delirium
26 Actively Recruiting
Phase 2, Phase 3, Not Applicable, Phase 4, Early Phase 1
phencyclidine
0 Actively Recruiting
severe Hyperactivity
0 Actively Recruiting

Haldol Reviews: What are patients saying about Haldol?

4.7Patient Review
12/21/2016
Haldol for Schizophrenia
Haldol has been a much better fit for me than other atypical medications I've tried, namely Abilify, Risperdal, and Geodon. It's made a big difference in my quality of life. There are some mild side effects that come with it (tremors, pacing, etc.) but nothing that I can't handle. If you're struggling with similar issues, I say give Haldol a shot.
4.3Patient Review
12/16/2016
Haldol for Mental Disorder with Loss of Normal Personality & Reality
I've been using this medication to great success for intrusive thoughts. The only downside is that it makes me really drowsy and my mouth is always dry.
4Patient Review
3/21/2016
Haldol for Brief Episode of Schizophrenia with Rapid Onset
I have to take a monthly injection of this medication, since I've been deemed non-compliant in the past. It's effective for my mood but unfortunately comes with the side effect of weight gain. My doctor tried to dismiss it but it happens to everyone I know on this medicine.
4Patient Review
5/9/2020
Haldol for Aggressive Behavior
I appreciate that Haldol doesn't cause me to gain a lot of weight.
2.7Patient Review
12/7/2018
Haldol for Tourette's
The tics I was experiencing slowed down, but the sedation effects were so strong that it interfered with my life more than the tics did. It got to the point where I would rather deal with the tics than take this medication.
2.3Patient Review
5/7/2021
Haldol for Schizophrenia
Haldol was terrible for me. I only experienced negative side effects and no benefits while taking it.
1Patient Review
8/7/2017
Haldol for Mental Disorder with Loss of Normal Personality & Reality
About six months ago, I started experiencing tremors in my left arm and hand. My doctor took me off the pill immediately, but the damage was already done. I now have difficulty talking and swallowing, and my life is ruined.
1Patient Review
1/27/2021
Haldol for Aggressive Behavior
I really dislike having to take this medication, and I resent the people who created it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about haldol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drug is Haldol?

"Haloperidol is a type of medication known as a conventional antipsychotic."

Answered by AI

Is Haldol a narcotic?

"Haloperidol is a psychoactive drug that has been widely used to treat schizophrenia, mania, neuroses, stuttering, and phobic states. It was developed by Janssen et al3 during experiments with synthetic narcotic agents."

Answered by AI

Is Haldol a strong sedative?

"and alprazolam (Xanax)

Haldol can cause sedation, which may be increased if it is combined with alcohol or other drugs that have sedative effects, such as benzodiazepines ( drugs used to treat anxiety, such as diazepam [Valium], lorazepam [Ativan], and alprazolam [Xanax])."

Answered by AI

What are the side effects for Haldol?

"To minimize dizziness, get up slowly from a lying down position

You may experience dizziness, lightheadedness, drowsiness, difficulty urinating, sleep disturbances, headache, and anxiety. If these effects persist or worsen, notify your doctor or pharmacist promptly. Dizziness and lightheadedness can increase your risk of falling. To avoid dizziness, get up slowly when rising from a sitting or lying position."

Answered by AI

Clinical Trials for Haldol

Image of Baylor College of Medicine in Houston, United States.

Stepped Care Treatment for Anxiety

7 - 17
All Sexes
Houston, TX
Childhood anxiety disorders (CAD) are common and impairing. Family based cognitive behavioral therapy (CBT) is efficacious in treating CAD. Yet, many children do not receive care due to barriers such as limited provider availably, high treatment costs, and constrained family resources (e.g., time). To combat these barriers, other treatment methods have been developed. The stepped care treatment models maximize resources by providing low-intensity, low-cost interventions as a first time treatment, while stepping up care for those needing more intensive treatment. Specifically, a stepped care model for CAD that begins with a parent-focus intervention has great promise to deliver efficacious and cost-effective treatment without having to engage the child. While stepped care approaches show promise in treating CAD with comparable efficacy to standard CBT, there remains a large research-to-practice gap. The stepped care model for CAD that begins with a parent-focused intervention has yet been explored, and very little is known about intervention mediators that explain mechanisms of change. This research is being done to improve the reach and quality of services using a stepped care model, offering an affordable and practical solution to the widespread gap in youth mental health care.
Waitlist Available
Has No Placebo
Baylor College of Medicine
Image of The University of Iowa in Iowa City, United States.

fMRI for Cognitive Flexibility

18 - 35
All Sexes
Iowa City, IA
The goal of this basic experimental research study is to examine how the human thalamus supports flexible thinking and behavior. Specifically, the research aims to elucidate how the mediodorsal (MD) thalamus encodes and updates "context"-the mental framework that determines which rules or actions are relevant in a given situation. This work may contribute to understanding why certain psychiatric conditions, such as schizophrenia and ADHD, involve difficulties with cognitive flexibility and control. The primary research questions are: Does the MD thalamus represent the context that organizes how working memory guides task selection? Does the MD thalamus signal when context needs to be updated after a change in task demands? Do these thalamic representations support generalization to new situations or rules? Participants will complete cognitive tasks while undergoing high-resolution brain imaging using 7-Tesla MRI. The investigators will combine behavioral data, computational modeling, and advanced neuroimaging analyses to examine how the thalamus interacts with the cortex during flexible decision-making.
Waitlist Available
Has No Placebo
The University of Iowa
Have you considered Haldol clinical trials? We made a collection of clinical trials featuring Haldol, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Brain Stimulation for Cannabis Craving in Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: Brain circuits most relevant to cannabis use in schizophrenia are distinct from pathways identified in healthy controls who use cannabis. This study seeks to provide evidence that targeted stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cue-induced craving and cognitive performance in individuals with schizophrenia and schizoaffective disorder, while targeted stimulation of the L DLPFC leads to these changes in healthy controls who use cannabis. This study will test a model that integrates brain network pathophysiology and cognition to 1) explain the prevalence of cannabis use in schizophrenia and 2) identify a target for engagement in schizophrenia. This study seeks to establish a neuroscientific framework to guide future treatment-oriented studies aimed at reducing craving and improving cognitive performance in individuals with schizophrenia and schizoaffective disorder. This is a study of the effect of 2 rTMS interventions on functional connectivity and craving in individuals with schizophrenia or schizoaffective disorder and healthy controls who use cannabis. Aim 1: Target Engagement: Determine if rTMS manipulates functional connectivity of each target (DMN, L DLPFC) (n=100). Aim 2: Clinical Efficacy: Determine if rTMS affects cue-induced craving and if craving change correlates with change in functional connectivity (n=100). As an exploratory analysis, the factors that explain individual variance in rTMS-induced connectivity change will also be explored.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric Hospital
Image of Vanderbilt Psychiatric Hospital in Nashville, United States.

Repetitive Transcranial Magnetic Stimulation for Schizophrenia

18 - 65
All Sexes
Nashville, TN
The central hypothesis is this: DMN connectivity can be modulated with inhibitory cTBS when delivered on an accelerated treatment schedule. This study seeks to provide evidence that accelerated, network-targeted inhibitory stimulation of the DMN leads to both altered network activity and a concomitant behavioral change in cognitive performance in individuals with schizophrenia and schizoaffective disorder. This study will also compare the effect of inhibitory cTBS in healthy individuals, as it may also lead to both altered network activity and a behavioral change in cognitive performance in individuals without schizophrenia or schizoaffective disorder. If successful, this study will have identified a safe, effective, and broadly applicable treatment for cognitive impairment in schizophrenia that has potential for translation into many other psychiatric and neurodevelopmental disorders, such as autism.
Waitlist Available
Has No Placebo
Vanderbilt Psychiatric HospitalHeather Ward, MD
Have you considered Haldol clinical trials? We made a collection of clinical trials featuring Haldol, we think they might fit your search criteria.Go to Trials
Image of Woodland International Research Group /ID# 275747 in Little Rock, United States.

Emraclidine for Schizophrenia

18 - 65
All Sexes
Little Rock, AR
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 258 participants will be enrolled across roughly 32 sites in the United States. Participants in Part A will be assigned to one of multiple ascending doses of emraclidine or placebo administered orally for 14 days or up to 21 days. Participants in Part B will receive Emraclidine or placebo administered orally for up to 42 days. Participants will be followed for 30 days after the last dose of the study drug. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Phase 2
Recruiting
Woodland International Research Group /ID# 275747 (+4 Sites)ABBVIE INC.AbbVie
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Focused Ultrasound for Anorexia

18 - 65
All Sexes
Toronto, Canada
The goal of this clinical trial is to evaluate the safety and initial clinical effectiveness of MRI-guided focused ultrasound (MRgFUS) thermal ablation (capsulotomy) in patients with treatment-refractory anorexia nervosa (AN) and comorbid obsessive-compulsive disorder (OCD) and major depressive disorder (MDD). The main questions it aims to answer are: 1. Can MR-guided focused ultrasound capsulotomy be safely delivered through an intact skull in patients with treatment-refractory anorexia nervosa and comorbid OCD and/or MDD, with a safety and side-effect profile comparable to traditional radiofrequency neurosurgical approaches? 2. Does MRgFUS capsulotomy produce clinical outcomes comparable to open surgical ablative procedures-specifically, improvements in anxiety, mood, quality of life, anorexia nervosa psychopathology, habit formation, and weight-in patients with treatment-refractory anorexia nervosa? Participants will: 1. Undergo baseline imaging and clinical assessments 2. Receive a single MRgFUS capsulotomy targeting the ALIC 3. Be monitored for 24 months post-treatment to assess adverse events, quality of life, and symptom changes using standardized clinical and neuropsychiatric measures
Phase 1
Recruiting
Sunnybrook Health Sciences Centre
Have you considered Haldol clinical trials? We made a collection of clinical trials featuring Haldol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security